PATUSKY CHRISTOPHER 4

What Happened

Christopher Patusky, a non-employee director of United Therapeutics (UTHR), was granted 2,380 derivative shares as an annual director award on July 22, 2026. The filing reports an acquisition price of $0 (award/grant, transaction code A). This was not an open-market purchase or sale but a routine compensation award for board service.

Key Details

• Transaction date: 2026-07-22; Filing date: 2026-07-23 (timely).
• Security: 2,380 shares reported as a derivative acquisition (code A); reported price $0.
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 = annual non-employee director award; F2 = awards vest on the earlier of (a) one year from the grant date or (b) the next Annual Meeting of Shareholders (anticipated June 25, 2027).
• No indication of 10b5-1 plan, tax withholding, or late filing in this report.

Context

Director awards like this are standard compensation and do not by themselves indicate a buy or sell signal from management. Purchases by insiders are generally more directly informative about personal conviction; grants are routine and typically subject to vesting conditions as noted above.